Carregant...
Mechanisms of failure of chimeric antigen receptor T-cell therapy
Although chimeric antigen receptor T (CART)-cell therapy is best recognized for its antitumor effect in relapsed/refractory B-cell hematological cancers, it is still associated with a high relapse rate. RECENT FINDINGS: We firstly analyzed internal immunological and genetic reasons of CD19+ relapse...
Guardat en:
| Publicat a: | Curr Opin Hematol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams And Wilkins
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6791516/ https://ncbi.nlm.nih.gov/pubmed/31577606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000548 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|